News | September 05, 2024
Apollo Hospitals launches Apollo Research Academy
The Academy, led by Professor Ravi P Mahajan CBE, is set to harmonize the efforts of various Apollo entities
The Academy, led by Professor Ravi P Mahajan CBE, is set to harmonize the efforts of various Apollo entities
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
New Phase II data show vast majority of patients experiencing no relapses or disability progression
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Phase 3 study results will form the basis for future discussions with global regulatory authorities
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
Subscribe To Our Newsletter & Stay Updated
